Group Overview
- Strong balance sheet maintained with
EUR 113 million net cash position - Business operations continue to be solid, with good performance across all business units
- Backlog remains high at
EUR 1.2 billion and new tenders continue to progress internationally with active discussions ongoing - Solid order intake with one Proteus®ONE1 and three Other Accelerators systems sold in the period with nine additional Other Accelerators systems sold and the first proton therapy order received from CGN Medical Technologies post-period end
- Expansion of Dosimetry offering with the acquisition of quality assurance (QA) company, Modus Medical Devices, post-period end
Proton Therapy
- 23 projects ongoing, with eight Proteus®PLUS2 and 15 Proteus®ONE systems in progress
- Strong pipeline continues across all geographies
- One new service contract in the quarter and a further post-period, with a total of 41 service contracts now generating recurring revenues globally
- One Proteus®ONE proton therapy solution contract signed
- Partnership with global engineering company, Tractebel, to support IBA’s customers with proton therapy design and construction projects
- Post-period end, IBA received its first order from CGN Medical Technologies for a Proteus®PLUS proton therapy system to be installed in Yangzhou,
China - Research collaboration with
University Medical Center Groningen (UMCG) for the development of a new FLASH irradiation protocol for the treatment of early-stage breast cancer - Ongoing expansion of Campus, the world’s first online proton therapy platform
Other Accelerators (RadioPharma, Industrial)
- Other Accelerators continued to perform strongly in the first quarter with three systems sold in the period and an additional nine sold post-period end
- Launch of a new low energy compact cyclotron, the Cyclone® KEY, improving access to diagnosis solutions in emerging market countries with in-house isotope production in hospitals
- Increasing demand for Rhodotron® for medical sterilization, with this part of the business performing particularly well
Dosimetry
- Very strong order intake with backlog remaining at a record high
- Collaborative agreement with Elekta to optimize quality assurance (QA) solutions of radiation therapy departments and clinics using Elekta’s treatment delivery systems
- Acquisition of Modus Medical Devices, specializing in phantoms for QA for radiation therapy, expanding the business unit’s service offering
Outlook
IBA has continued to perform well across all business lines in the first quarter of 2022. Our pipeline remains highly active, particularly in the US and
We have seen a modest impact from the ongoing conflict in
Financial calendar
Half year Results
Business Update Q3 2022
About IBA
IBA (
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
For further information, please contact:
IBA
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com
Corporate Communication Director
+32 10 475 890
communication@iba-group.com
For media and investor enquiries:
+44 (0) 20 3709 5700
IBA@consilium-comms.com
1 Proteus®ONE is a brand name of Proteus®235
2 Proteus®PLUS is a brand name of Proteus®235
Attachment
- 220519-IBA-Q1-Business-Update-EN
© OMX, source